• Home
  • Search Results
  • A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.

A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.

The Journal of urology (2013-10-19)
Joseph R Osborne, David A Green, Daniel E Spratt, Serge Lyashchenko, Shoaib B Fareedy, Brian D Robinson, Bradley J Beattie, Manu Jain, Jason S Lewis, Paul Christos, Steven M Larson, Neil H Bander, Douglas S Scherr
ABSTRACT

In this pilot study we explored the feasibility of (89)Zr labeled J591 monoclonal antibody positron emission tomography of localized prostate cancer. Before scheduled radical prostatectomy 11 patients were injected intravenously with (89)Zr-J591, followed 6 days later by whole body positron emission tomography. Patients underwent surgery the day after imaging. Specimens were imaged by ex vivo micro positron emission tomography and a custom 3 Tesla magnetic resonance scanner coil. Positron emission tomography images and histopathology were correlated. Median patient age was 61 years (range 47 to 68), median prostate specific antigen was 5.2 ng/ml (range 3.5 to 12.0) and median biopsy Gleason score of the 11 index lesions was 7 (range 7 to 9). On histopathology 22 lesions were identified. Median lesion size was 5.5 mm (range 2 to 21) and median Gleason score after radical prostatectomy was 7 (range 6 to 9). Eight of 11 index lesions (72.7%) were identified by in vivo positron emission tomography. Lesion identification improved with increasing lesion size for in vivo and ex vivo positron emission tomography (each p <0.0001), and increasing Gleason score (p = 0.14 and 0.01, respectively). Standardized uptake values appeared to correlate with increased Gleason score but not significantly (p = 0.19). To our knowledge this is the first report of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in localized prostate cancer cases. In this setting (89)Zr-J591 bound to tumor foci in situ and positron emission tomography identified primarily Gleason score 7 or greater and larger tumors, likely corresponding to clinically significant disease warranting definitive therapy. A future, larger clinical validation trial is planned to better define the usefulness of (89)Zr-J591 positron emission tomography for localized prostate cancer.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Zirconium, powder, −100 mesh
Sigma-Aldrich
Zirconium, foil, thickness 0.1 mm, 99.98% trace metals basis
Sigma-Aldrich
Zirconium, sponge, ≥99% trace metals basis
Sigma-Aldrich
Zirconium, rod, diam. 6.35 mm, ≥99% trace metals basis
Zirconium, rod, 100mm, diameter 50mm, centerless ground, 99.2%
Zirconium, foil, not light tested, 50x50mm, thickness 0.006mm, 99.2%
Zirconium, rod, 1000mm, diameter 1.5mm, 99.2%
Zirconium, rod, 1000mm, diameter 12.7mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 2.0mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 3.0mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 5.0mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 6.0mm, centerless ground, 99.2%
Zirconium, rod, 1000mm, diameter 9.5mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 1.5mm, 99.2%
Zirconium, rod, 100mm, diameter 12.7mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 19.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 2.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 3.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 5.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 6.0mm, centerless ground, 99.2%
Zirconium, rod, 100mm, diameter 9.5mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 1.5mm, 99.2%
Zirconium, rod, 200mm, diameter 12.7mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 19.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 2.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 3.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 5.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 6.0mm, centerless ground, 99.2%
Zirconium, rod, 200mm, diameter 9.5mm, centerless ground, 99.2%
Zirconium, rod, 500mm, diameter 1.5mm, 99.2%

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.